DocMorris launches approx. CHF 200 million Convertible Bonds due 2029 – Biotech Investments

DocMorris AG / Key word(s): Bond

17-Apr-2024 / 17:46 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.

Under the following link you will find our press release about launching an offering of convertible bonds:

https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024

End of Inside Information

My four kids and I all have ADHD. We need telehealth options

On Thursday, the CDC released new data showing that almost 15.5 million U.S. adults are living with ADHD. More than half of those individuals received

October 10, 2024

Candid inks three T cell engager deals; PepGen trial put on hold

Plus, news about Foghorn Therapeutics, Incyte, BioNTech, Galderma, Basilea, Innovia, Pharming, bit.bio, Promise Bio, Outlook Therapeutics and Trevi Therapeutics: Candid Therapeutics’ trio of T cell

December 17, 2024

Red Light Holland Announces NCIB Update and Live Q&A with CEO Todd Shapiro and CFO Jon Szczur on September 26th | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – September 23, 2024) – Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) (“Red Light” or the “Company”), an Ontario-based

September 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.